康基醫療(09997.HK)逾3.6億人幣售醫療器械業務
康基醫療(09997.HK)公布,其間接全資附屬Hangzhou Kangji Medical Instrument,向Hangzhou Yonghao Carefree Cultural Development出售醫療器械分銷及研發公司Hangzhou Kangji Qipu Medical Instrument的全部股權,總代價為3.66億元人民幣(下同),預期集團錄得收益約4,150萬元。
公司指出,由於集團業務計劃變更,集團擬變現目標公司持有的資源,並利用該等資源發展其現有業務。出售事項的所得款項現擬由集團用作一般企業用途。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.